Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase II clinical trial of the SYS 6026 injection (this product) developed by the Group to treat high-grade cervical squamous intraepithelial lesion (HSIL) related to human papillomavirus (HPV) type 16 or 18 has been officially launched in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.